TheraRadar
Data updated: May 26, 2026

CLODERM (clocortolone pivalate)

Dermatology Approved 1977-08-22

CLODERM is indicated for the treatment of Dermatoses.

Source: FDA Label • LEGACY PHARMA
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
48
Years on Market

Details

Status
Prescription
First Approved
1977-08-22
Routes
TOPICAL
Dosage Forms
CREAM

Companies

LEGACY PHARMA
Active Ingredient: CLOCORTOLONE PIVALATE

CLODERM Approval History

1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
25 FDA actions from 1977 to 2009
May 2009 SUPPL
Mfg · Manufacturing (CMC)
Feb 2008 SUPPL
Mfg · Manufacturing (CMC)
Dec 2003 SUPPL
Mfg · Manufacturing (CMC)
FDA Letter Label

What CLODERM Treats

1 indications

CLODERM is approved for 1 conditions since its original approval in 1977. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dermatoses
Source: FDA Label

CLODERM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

10

Same indication, different mechanism — what else might this patient receive?

HALOBETASOL PROPIONATE AND TAZAROTENE
SUN PHARMA
2025 1 indic.
HALCINONIDE
ENCUBE
2019 1 indic.
Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CLODERM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALA-SCALP
HYDROCORTISONE
1 shared
LEGACY PHARMA
Shared indications:
Dermatoses
ALCLOMETASONE DIPROPIONATE
ALCLOMETASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
Dermatoses
AMCINONIDE
AMCINONIDE
1 shared
TARO PHARM INDS
Shared indications:
Dermatoses
View all 20 similar drugs Pro
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT04358770 CLPC-1801 Ph 1 completed Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLODERM FDA Label Details

Indications & Usage

FDA Label (PDF)

CLODERM is indicated for the treatment of Dermatoses.

Track CLODERM with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA017765 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.